USD
$0.00
(0.00%
)At Close (As of Sep 15, 2025)
$8.55B
Market Cap
19.37
P/E Ratio
0.51
EPS
$10.96
52 Week High
$6.09
52 Week Low
HEALTHCARE
Sector
Field | Value (EUR) |
---|---|
Gross Profit | $2.8B |
Total Revenue | $7.2B |
Cost Of Revenue | $4.4B |
Costof Goods And Services Sold | $4.4B |
Operating Income | $1.2B |
Selling General And Administrative | $1.1B |
Research And Development | $384M |
Operating Expenses | $1.6B |
Investment Income Net | - |
Net Interest Income | -$701M |
Interest Income | $44M |
Interest Expense | $773M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $438M |
Income Before Tax | $444M |
Income Tax Expense | $231M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $213M |
Comprehensive Income Net Of Tax | - |
Ebit | $1B |
Ebitda | $1.5B |
Net Income | $157M |
Field | Value (EUR) |
---|---|
Total Assets | $21B |
Total Current Assets | $5.7B |
Cash And Cash Equivalents At Carrying Value | $980M |
Cash And Short Term Investments | $980M |
Inventory | $3.6B |
Current Net Receivables | $1.1B |
Total Non Current Assets | $16B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $2.9B |
Intangible Assets Excluding Goodwill | $2.9B |
Goodwill | $7.4B |
Investments | - |
Long Term Investments | $529M |
Short Term Investments | $21M |
Other Current Assets | $87M |
Other Non Current Assets | - |
Total Liabilities | $13B |
Total Current Liabilities | $2.2B |
Current Accounts Payable | $852M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $640M |
Total Non Current Liabilities | $11B |
Capital Lease Obligations | $1.1B |
Long Term Debt | $8.4B |
Current Long Term Debt | $523M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $10B |
Other Current Liabilities | $508M |
Other Non Current Liabilities | $45M |
Total Shareholder Equity | $5.9B |
Treasury Stock | - |
Retained Earnings | $157M |
Common Stock | $120M |
Common Stock Shares Outstanding | $680M |
Field | Value (EUR) |
---|---|
Operating Cashflow | $902M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $438M |
Capital Expenditures | $371M |
Change In Receivables | - |
Change In Inventory | $26M |
Profit Loss | - |
Cashflow From Investment | $887M |
Cashflow From Financing | -$1.4B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $962K |
Dividend Payout Common Stock | $962K |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $0 |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $444M |
Field | Value (EUR) |
---|---|
Gross Profit | $2.8B |
Total Revenue | $7.2B |
Cost Of Revenue | $4.4B |
Costof Goods And Services Sold | $4.4B |
Operating Income | $1.2B |
Selling General And Administrative | $1.1B |
Research And Development | $384M |
Operating Expenses | $1.6B |
Investment Income Net | - |
Net Interest Income | -$701M |
Interest Income | $44M |
Interest Expense | $773M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $438M |
Income Before Tax | $444M |
Income Tax Expense | $231M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $213M |
Comprehensive Income Net Of Tax | - |
Ebit | $1B |
Ebitda | $1.5B |
Net Income | $157M |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-12 |
Declaration Date | 2025-07-30 |
Record Date | 2025-08-12 |
Payment Date | 2025-08-20 |
Amount | 0.175789 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.